Athira Pharma logo
Athira Pharma
ATHA | NASDAQ
Chart Builder DCF Calculator
$6.75
-$0.44 (-6.12%)
At close: Jan 09, 2026, 04:00 PM ET

Athira Pharma Company Profile

Company profile explained

Company Profile

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.

Key Executives

Name Position
Mark J. Litton President, Chief Executive Officer & Director
Robert Renninger Chief Financial Officer
Javier San Martin Chief Medical Officer
Julie Rathbun Head of Investor Relations
Kevin Church Chief Scientific Officer
Mark F. Worthington General Counsel, Chief Compliance Officer & Corporate Secretary

Latest SEC Filings

Date Type Title
Sep 22, 2026 8-K Current Report
Sep 03, 2026 3 Filing
Aug 31, 2026 SC 13D Filing
Aug 26, 2026 8-K Current Report
Aug 25, 2026 SC 13D/A [Amend] Filing
Aug 20, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 10-Q Quarterly Report
Aug 14, 2026 8-K Current Report
Jul 10, 2026 4 Filing
Jul 09, 2026 4 Filing
View All SEC Filings ➞
Athira Pharma
Athira Pharma logo
Country United States
IPO Date Sep 18, 2020
Industry Biotechnology
Sector Healthcare
Employees 26
CEO Mark J. Litton

Contact Details

18706 North Creek Parkway Bothell, Washington 98011 United States

Stock Details

Ticker Symbol ATHA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001620463
CUSIP Number 04746L203
ISIN Number US04746L2034
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.